On the stock market since 2017, it operates in the world of health and science. It has 59 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
This grade is a blend: the profit side is strong, the sales tempo slow.
Clearly below the class average.
Business Quality: Profit power and business quality trail similar companies in the sector.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: Right now the product sells for less than it costs to make; every sale deepens the loss.
An investor who bought at the very peak is down 86% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $41K a year. A small number, but proof the product has real buyers.
There is $273.5M in the vault; even if every debt were paid off, $237.8M would remain.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
A loss of $88.1M against $41K in annual sales.
Measured against its sector, the quality of the business sits below the class average. Report-card grade: 14/100.
Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 28/100. For a turnaround signal, the stock first needs to close the gap with the market.
On our five-subject report card, ALT sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: ALT is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (46/100) says the stock isn’t cheap.